{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T13:40:28Z","timestamp":1794577228350,"version":"4.9.1"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Global Health"],"DOI":"10.1186\/s12992-025-01176-7","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T03:17:07Z","timestamp":1765941427000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["From proposal to compromise: the TRIPS waiver debate and the crisis of WTO decision-making"],"prefix":"10.1186","volume":"22","author":[{"given":"Nirmalya","family":"Syam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Zaheer","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"1176_CR1","first-page":"360","volume-title":"Access to medicines and vaccines","author":"KD Raju","year":"2021","unstructured":"Raju KD. Patent linkages and its impact on access to medicines: challenges, opportunities for developing countries. In: Shaikh B, editor. Access to medicines and vaccines. Singapore: Springer; 2021. p. 360."},{"key":"1176_CR2","doi-asserted-by":"crossref","unstructured":"Gurgula O. Strategic patenting by pharmaceutical companies - Should competition law intervene? IIC Int Rev Intellect Prop Compet Law. 2020;51. p. 1065.","DOI":"10.1007\/s40319-020-00985-0"},{"key":"#cr-split#-1176_CR3.1","unstructured":"Marrakesh Agreement Establishing the World Trade Organization. 1867 UNTS 3"},{"key":"#cr-split#-1176_CR3.2","unstructured":"entered into force. 1995, Jan, 1 Art IX(3)."},{"key":"1176_CR4","unstructured":"Correa CM, Syam N. The WTO TRIPS Decision on COVID-19 vaccines: what is needed to implement it? Research paper No. 169. Geneva: South Centre; 2022 [cited 2025 Dec 10]. Available from: https:\/\/www.southcentre.int\/wp-content\/uploads\/2022\/11\/RP169_The-WTO-TRIPS-Decision-on-COVID-19-Vaccines_EN.pdf."},{"issue":"1","key":"1176_CR5","first-page":"1","volume":"14","author":"T \u2019t Hoen Ef","year":"2021","unstructured":"\u2019t Hoen Ef T, Boulet P, Baker BK. Data exclusivity exceptions and compulsory licensing to promote generic medicines in the COVID-19 era. J Pharm Policy Pract. 2021;14(1):1\u20135.","journal-title":"J Pharm Policy Pract"},{"key":"1176_CR6","unstructured":"World Health Organization. WHO COVID-19 dashboard [Internet]. Available from: https:\/\/data.who.int\/dashboards\/covid19\/deaths."},{"key":"1176_CR7","unstructured":"Amnesty International. Inequality of pandemic proportions: state and Pharma failures not to Be repeated. POL 30\/6518\/2023. 2023;6."},{"key":"1176_CR8","unstructured":"Our World in data. Coronavirus (COVID-19) vaccinations [Internet]. Available from: https:\/\/ourworldindata.org\/explorers\/coronavirus-data-explorer?zoomToSelection=true%26time=latest%26facet=none%26country=OWID_WRL%Low+income%Lower+middle+income%Upper+middle+income%High+income%26pickerSort=desc%26pickerMetric=population%26hideControls=true%26Metric=People+vaccinated+(by+dose)%26Interval=Cumulative%26Relative+to+Population=true&Color+by+test+positivity=false."},{"key":"1176_CR9","unstructured":"United Nations. Secretary-General calls for Early action to avoid world of \u2018Vaccine haves and have-nots, at African COVID-19 strategy meeting. SG\/SM\/20557. 2021. Available from: https:\/\/press.un.org\/en\/2021\/sgsm20557.doc.htm."},{"key":"1176_CR10","doi-asserted-by":"crossref","unstructured":"Fischer SE, et al. Intellectual property and the politics of public good in COVID-19: framing law, institutions, and ideas during TRIPS waiver negotiations at the WTO. J Health Polit Policy Law. 2024;49(1).","DOI":"10.1215\/03616878-10910269"},{"key":"1176_CR11","unstructured":"United Nations. Amid COVID-19 pandemic, General Assembly, in silence procedure, adopts 7 Resolutions, 13 Decisions between 27 March and 14 May. GA\/12244. 2020. Available from: https:\/\/press.un.org\/en\/2020\/ga12244.doc.htm."},{"key":"1176_CR12","unstructured":"G20 research group. Extraordinary G20 leaders\u2019 summit: statement on COVID-19. Saudi Arabia. 2020 Mar 26. Available from: http:\/\/www.g20.utoronto.ca\/2020\/2020-g20-statement-0326.html."},{"key":"1176_CR13","first-page":"30","volume-title":"Reforming intellectual property","author":"P Drahos","year":"2022","unstructured":"Drahos P. Public lies and public goods: Ten lessons from when patents and pandemics meet. In: Ghidini G, Falce V, editors. Reforming intellectual property. Cheltenham and Northampton (Ma.): Edward Elgar Publishing; 2022. p. 30\u201344."},{"key":"1176_CR14","unstructured":"Syam N. The un General Assembly Resolutions on COVID-19: solemn assurances for access to health technologies without an action plan. Policy brief No.81. Geneva: South Centre 2020. Available from: https:\/\/www.southcentre.int\/wp-content\/uploads\/2020\/07\/PB-81.pdf."},{"key":"1176_CR15","unstructured":"Abbas MZ. Practical implications of vaccine Nationalism: a short-sighted and risky approach in response to COVID-19. Research paper 124. Geneva: South Centre; 2020. Available from: https:\/\/www.southcentre.int\/research-paper-124-november-2020\/."},{"key":"1176_CR16","unstructured":"World Health Organization. COVID-19 technology access pool [Internet]. Available from: https:\/\/www.who.int\/initiatives\/covid-19-technology-access-pool."},{"key":"1176_CR17","unstructured":"World Health Organization. C-TAP: A concept paper. 2020, Oct, 27. Available from: https:\/\/www.who.int\/publications\/m\/item\/c-tap-a-concept-paper."},{"key":"1176_CR18","unstructured":"International Federation of pharmaceutical manufacturers %26 Associations. Statement on the \u201csolidarity call to action to realize equitable global access to COVID-19 health technologies through pooling of knowledge, intellectual property and data\u201d. 2020 May 28. Available from: https:\/\/www.ifpma.org\/news\/ifpma-statement-on-the-solidarity-call-to-action-to-realize-equitable-global-access-to-covid-19-health-technologies-through-pooling-of-knowledge-intellectual-property-and-data\/."},{"key":"1176_CR19","unstructured":"Baker BK, Thrasher RD. From Business as usual to health for the future: challenging the intellectual property regime to address COVID-19 and future pandemics. Boston Univ Int Law J. 2023;41(1)."},{"key":"1176_CR20","unstructured":"World Trade Organization. Council for TRIPS. Minutes of Meeting. IP\/C\/M\/96\/Add.1. WTO document IP\/C\/W\/669. 2020 Oct 2."},{"key":"1176_CR21","unstructured":"WTO TRIPS Council. Waiver from certain provisions of the TRIPS Agreement for the prevention, containment and treatment of COVID-19: communication from India and South Africa. IP\/C\/W\/669; 2020 Oct 2."},{"key":"1176_CR22","unstructured":"World Trade Organization. General Council. Minutes of Meeting. WT\/GC\/M\/188."},{"key":"1176_CR23","unstructured":"WTO General Council. Remarks by DG Okonjo-Iweala on the IP waiver. 2021 May 5. Available from: https:\/\/www.wto.org\/english\/news_e\/spno_e\/spno9_e.htm."},{"key":"1176_CR24","unstructured":"United States Trade Representative. COVID-19 TRIPS waiver. Press statement. 2021 May 5."},{"key":"1176_CR25","unstructured":"White House. Fact sheet: biden-harris administration is providing at least 80 million COVID-19 vaccines for global use, commits to leading a multilateral effort toward ending the pandemic. 2021 May 17. Available from: https:\/\/www.whitehouse.gov\/briefing-room\/statements-releases\/2021\/05\/17\/fact-sheet-biden-harris-administration-is-providing-at-least-80-million-covid-19-vaccines-for-global-use-commits-to-leading-a-multilateral-effort-toward-ending-the-pandemic\/."},{"key":"1176_CR26","volume-title":"Waiver from certain provisions of the TRIPS Agreement for the Prevention, Containment and treatment of COVID-19: communication from India and South Africa","author":"WTO TRIPS Council","year":"2021","unstructured":"WTO TRIPS Council. Waiver from certain provisions of the TRIPS Agreement for the Prevention, Containment and treatment of COVID-19: communication from India and South Africa. IP\/C\/W\/669\/Rev.1; 2021 May 25."},{"key":"1176_CR27","unstructured":"WTO TRIPS Council. IP\/C\/W\/681; 2021 Jun 18."},{"key":"1176_CR28","unstructured":"Correa CM, Syam N, Uribe D. Implementation of a TRIPS waiver for health technologies and products for COVID-19: preventing claims under free Trade and investment agreements. Research paper No.135.South Centre Geneva;2021. p. 1. Available from: https:\/\/www.southcentre.int\/research-paper-135-september-2021\/."},{"issue":"2","key":"1176_CR29","first-page":"23","volume":"14","author":"B Kampmark","year":"2022","unstructured":"Kampmark B. Intellectual property, COVID-19 vaccines and equity: a public health and human rights critique. Aust N Z J Eur Stud. 2022;14(2):23.","journal-title":"Aust N Z J Eur Stud"},{"key":"1176_CR30","unstructured":"Rosen M. Confronting Joe Biden\u2019s proposed TRIPS waiver for COVID-19 vaccines and treatments: highlights from an expert panel discussion. Aeideas. 2021 Jul 2. Available from: https:\/\/www.aei.org\/technology-and-innovation\/confronting-joe-bidens-proposed-trips-waiver-for-covid-19-vaccines-and-treatments-highlights-from-an-expert-panel-discussion\/."},{"key":"1176_CR31","unstructured":"WTO TRIPS Council. Questions on intellectual property challenges experienced by Members in relation to COVID-19: communication from Australia, Canada, Chile and Mexico. IP\/C\/W\/671. 2020 Nov 27."},{"key":"1176_CR32","unstructured":"G20. Leaders\u2019 Declaration, G20 Riyadh Summit.. Paragraph 3. Available from: 2020 Nov 21\u201322. https:\/\/www.consilium.europa.eu\/media\/46883\/g20-riyadh-summit-leaders-declaration_en.pdf."},{"key":"1176_CR33","unstructured":"Letter to Ambassador Katherine C. Tai. United States Trade Representative. Re: United States facilitation of the TRIPS waiver. 2021 May 15. Copy With Author. 2."},{"key":"1176_CR34","unstructured":"Information Technology & Innovation Foundation. COVID-19 diagnostics and therapeutics: supply, demand, and TRIPS Agreement flexibilities. Post-hearing Comments of Stephen Ezell. FR Doc. 2023-02466. 2023. p. 6."},{"key":"1176_CR35","unstructured":"Abbott AF, McDanial C. A WTO TRIPS Agreement waiver to promote the dissemination of COVID-19 diagnostics and therapeutics is unneeded and would impose harm. U.S. International Trade Commission Investigation No. p. 332\u2013596."},{"key":"1176_CR36","unstructured":"Third World Network. re: post hearing Brief by Third World Network -. Investigation No. 332-596. 2023 Apr 12. p. 6."},{"key":"1176_CR37","unstructured":"World Intellectual Property Organization. Patent landscape report: COVID-19-related vaccines and therapeutics: insights into related patenting activity throughout the pandemic. 2023;12."},{"key":"1176_CR38","unstructured":"Breuninger K. Pfizer CEO opposes U.S. call to waive covid vaccine patents, cites manufacturing and safety issues. CNBC. 2021 May 7. Available from: https:\/\/www.cnbc.com\/2021\/05\/07\/pfizer-ceo-biden-backed-covid-vaccine-patent-waiver-will-cause-problems.html."},{"key":"1176_CR39","unstructured":"Iancu A, Locke G, Kappos DJ. The shot heard around the World. Center for strategic and international studies. 2021 Nov 17. Available from: https:\/\/www.csis.org\/analysis\/shot-heard-around-world."},{"key":"1176_CR40","unstructured":"Biotechnology Innovation Organization. Re: COVID-19 Diagnostics and therapeutics: supply, demand, and TRIPS Agreement flexibilities. ITC Investigation No. 332-596. Letter to Katherine M. Hiner. 2023 May 5. p. 6."},{"key":"1176_CR41","unstructured":"Public Citizen. Re: written Comments for Investigation No. 332-596. COVID-19 diagnostics and therapeutics and flexibilities under the TRIPS Agreement. 2023, May, 5;1."},{"key":"1176_CR42","unstructured":"MSF access Campaign. Latin America: how patents and licensing hinder access to COVID-19 treatments. 2022 Mar 8. Available from: https:\/\/msfaccess.org\/latin-america-how-patents-and-licensing-hinder-access-covid-19-treatments."},{"key":"1176_CR43","unstructured":"U.S. International Trade Commission. COVID-19 diagnostics and therapeutics: supply, demand and TRIPS Agreement flexibilities. 2023 Oct.Washington, D.C. p. 178. Available from : https:\/\/www.usitc.gov\/publications\/332\/pub5469.pdf."},{"key":"1176_CR44","unstructured":"Civil society organizations. Letter to WTO and WHO Directors-General and WTO Members. 2021 Apr 13."},{"key":"1176_CR45","doi-asserted-by":"crossref","unstructured":"Abbott F. TRIPS Agreement article 73 security exceptions and the COVID-19 pandemic. Research paper No.116. 2020. Geneva: South Centre. Available from: https:\/\/www.southcentre.int\/wp-content\/uploads\/2020\/08\/RP-116.pdf.","DOI":"10.2139\/ssrn.3682260"},{"key":"1176_CR46","unstructured":"De Menezes HZ. The TRIPS waiver proposal: an urgent measure to expand access to the COVID-19 vaccines. Research paper No. 129. Geneva: South Centre; 2021. p. 9. Available from: https:\/\/www.southcentre.int\/research-paper-129-march-2021\/."},{"key":"1176_CR47","unstructured":"Doctors without Borders. WTO COVID-19 TRIPS waiver. Doctors without Borders Canada briefing note. 2021 Mar 9;3."},{"key":"1176_CR48","doi-asserted-by":"crossref","unstructured":"Thambisetty S, et al. The TRIPS intellectual property waiver proposal: creating the right incentives in patent law and politics to end the COVID-19 pandemic. LSE legal studies working paper No. 6. 2021.","DOI":"10.2139\/ssrn.3851737"},{"key":"1176_CR49","first-page":"1","volume":"1","author":"MZ Abbas","year":"2013","unstructured":"Abbas MZ, Riaz S. TRIPS flexibilities: implementation Gaps between Theory and practice. Nord J Commer Law. 2013;1:1\u201325.","journal-title":"Nord J Commer Law"},{"key":"1176_CR50","unstructured":"Office of the United States Trade Representative. Special 301 report. 2020 Apr. Available from: https:\/\/ustr.gov\/sites\/default\/files\/2020_Special_301_Report.pdf."},{"key":"1176_CR51","unstructured":"Silverman E. Pfizer faces criticism for arguing that intellectual property for its covid-19 pill is a human right. Stat news. 2022 Apr 20. Available from: https:\/\/www.statnews.com\/pharmalot\/2022\/04\/20\/patent-pfizer-covid19-patent-paxlovid-dominican-republic\/."},{"issue":"1\u20132","key":"1176_CR52","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/jwip.12083","volume":"21","author":"MZ Abbas","year":"2018","unstructured":"Abbas MZ, Riaz S. WTO \u2018Paragraph 6\u2019 system for affordable access to medicines: relief or regulatory ritualism? J World Intellect Prop. 2018;21(1\u20132):32\u201351.","journal-title":"J World Intellect Prop"},{"key":"1176_CR53","unstructured":"MSF access Campaign. Neither expeditious, nor a solution: the WTO August 30th Decision is unworkable. 2006 Aug 30. Available from: https:\/\/msfaccess.org\/neither-expeditious-nor-solution-wto-august-30th-decision-unworkable."},{"key":"1176_CR54","unstructured":"Abbas MZ. Canada\u2019s political choices restrain vaccine equity: the Bolivia-Biolyse case. Research paper No. 136. Geneva: South Centre; 2021. Available from: https:\/\/www.southcentre.int\/research-paper-136-september-2021\/."},{"key":"1176_CR55","unstructured":"United Nations Secretary-General\u2019s high-level panel on access to medicines. Report of the United Nations Secretary-General\u2019s high-level panel on access to medicines. Promoting innovation and access to health technologies. 2016. Available from: https:\/\/www.un.org\/sg\/en\/hlpanel\/healthtechnology."},{"key":"1176_CR56","unstructured":"Correa CC. Guide for the granting of compulsory licenses and government use of pharmaceutical patents. Research paper No.107. Geneva: South Centre 2021. Available from: https:\/\/www.southcentre.int\/research-paper-107-january-2021\/."},{"key":"1176_CR57","doi-asserted-by":"crossref","unstructured":"Pitts PJ, Popovian R, Winegarden W. Waiving COVID-19 vaccine patents: a bad idea and a dangerous precedent. J Commer Biotechnol. 2021;26(2).","DOI":"10.5912\/jcb987"},{"key":"1176_CR58","unstructured":"Citizens against government waste. Re: COVID-19 diagnostics and therapeutics: supply, demand, and TRIPS Agreement flexibilities. (Inv. No. 332-596). 2023 May 4;2."},{"key":"1176_CR59","unstructured":"Boldrin M, Levine DK. Economic and game Theory against intellectual monopoly. 2007 Jan 22. Available from: http:\/\/www.dklevine.com\/general\/intellectual\/againstnew.htm."},{"key":"1176_CR60","doi-asserted-by":"publisher","unstructured":"Kumraj G, Pathak S, Shah S, Majumder P, Jain J, Bhati D, Hanif S, Mukherjee S, Ahmed S. Capacity building for vaccine manufacturing across developing countries; the way forward. Hum Vaccin Immunother. 2022;18(1). Available from: https:\/\/doi.org\/10.1080\/21645515.2021.2020529.","DOI":"10.1080\/21645515.2021.2020529"},{"issue":"1","key":"1176_CR61","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1257\/jep.27.1.23","volume":"27","author":"P Moser","year":"2013","unstructured":"Moser P. Patents and innovation: evidence from economic history. J Econ Perspectives. 2013;27(1):23\u201344. Available from: https:\/\/www.aeaweb.org\/articles?id=10.1257%2Fjep.27.1.23.","journal-title":"J Econ Perspectives"},{"key":"1176_CR62","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1146\/annurev-economics-080315-015136","volume":"8","author":"P Moser","year":"2016","unstructured":"Moser P. Patents and innovation in economic history. Annu Rev Econ. 2016;8:241\u201358.","journal-title":"Annu Rev Econ"},{"key":"1176_CR63","doi-asserted-by":"crossref","unstructured":"Aquino-Jarquin G. The patent dispute over the breakthrough mRNA technology. Front Bioeng Biotechnol. 2022;10.","DOI":"10.3389\/fbioe.2022.1049873"},{"key":"1176_CR64","doi-asserted-by":"crossref","unstructured":"Kumar M, Bharti N. Why patent waiver for COVID-19 vaccines and pharmaceuticals? J World Intellect Prop. 2023.","DOI":"10.1111\/jwip.12269"},{"key":"1176_CR65","unstructured":"Wallach L, U.S. International Trade Commission Investigation No. 332-596. COVID-19 diagnostics and therapeutics: supply, demand, and TRIPS Agreement flexibilities. Rethink Trade, Am Econ Liberties Project. 2023;5."},{"key":"1176_CR66","doi-asserted-by":"crossref","unstructured":"Gurgula O. Compulsory licensing vs. The IP waiver: what is the best way to end the COVID-19 pandemic? Policy Brief 104. Geneva: South Centre; 2021. p. 6. Available from: https:\/\/www.southcentre.int\/policy-brief-104-october-2021\/.","DOI":"10.2139\/ssrn.3944192"},{"key":"1176_CR67","unstructured":"World Trade Organization. Draft Ministerial Decision on the TRIPS Agreement. WT\/MIN(22)\/W\/15\/Rev.2. 2022 Jun 17. para. 1. Available from: https:\/\/docs.wto.org\/dol2fe\/Pages\/SS\/directdoc.aspx?filename=q:\/WT\/MIN22\/W15R2.pdf%26Open=True."},{"key":"1176_CR68","unstructured":"Love J. The proposed TRIPS compromise risks setting several bad precedents. Bill of Health. 2022 Apr 7. Available from: https:\/\/blog.petrieflom.law.harvard.edu\/2022\/04\/07\/trips-compromise-bad-precedents\/."},{"key":"1176_CR69","unstructured":"Vawda Y, Hassan F, Johnson T. New WTO deal is a slap in the face for poorer countries. News24. 2022 Jun 18 [cited 2025 Dec 10]. Available from:https:\/\/www.news24.com\/fin24\/opinion\/opinion-new-wto-deal-is-a-slap-in-the-face-for-poorer-countries-20220618."},{"key":"1176_CR70","unstructured":"Delhi PIB. Statement by Shri Piyush Goyal during the WTO. 12th Ministerial Conference at the meeting with co-sponsors of TRIPS Waiver. Ministry of Commerce and Industry, India. Available from: https:\/\/pib.gov.in\/PressReleasePage.aspx?PRID=1834066."},{"key":"1176_CR71","unstructured":"World Trade Organization. Decision of 14 November, 2001: European communities - the ACP-EC partnership Agreement. WT\/MIN(01)\/15. Geneva: WTO 2001. Available from: https:\/\/www.wto.org\/english\/thewto_e\/minist_e\/min01_e\/mindecl_acp_ec_agre_e.htm."},{"key":"1176_CR72","unstructured":"Council for Trade-related Aspects of intellectual property rights. Revised submission by TRIPS waiver Co-sponsors. WTO doc WT\/GC\/W\/920. 2022 May 20."},{"key":"1176_CR73","unstructured":"Office of the U.S. Trade Representative. Ambassador Tai requests USITC Investigation of COVID-19 diagnostics and therapeutics. 2022 Dec 16. Available from: https:\/\/ustr.gov\/about-us\/policy-offices\/press-office\/press-releases\/2022\/december\/ambassador-tai-requests-usitc-investigation-covid-19-diagnostics-and-therapeutics."},{"key":"1176_CR74","unstructured":"World Health Organization. Strategic preparedness, readiness and response plan to end the global COVID-19 emergency in 2022. Geneva: World Health Organization; 2022 Mar 30 [cited 2025 Dec 10]. Available from:https:\/\/www.who.int\/publications\/i\/item\/WHO-WHE-SPP-2022.1."},{"key":"1176_CR75","unstructured":"World Health Organization. Statement on the fourteenth meeting of the international health regulations (2005) emergency committee regarding the coronavirus disease (COVID-19) pandemic. https:\/\/www.who.int\/news\/item\/30-01-2023-statement-on-the-fourteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic. 2023 Jan 30. Available from."},{"key":"1176_CR76","unstructured":"World Health Organization. WHO Director-General\u2019s opening remarks at the WHO, WIPO, WTO joint technical symposium on the COVID-19 pandemic: response, preparedness, resilience. 2022 Dec 16 [cited 2025 Dec 10]. Available from: https:\/\/www.who.int\/director-general\/speeches\/detail\/who-director-general-s-opening-remarks-at-the-who-wipo-wto-joint-technical-symposium-on-the-covid-19-pandemic-response-preparedness-resilience-16-december-2022."},{"key":"1176_CR77","unstructured":"World Health Organization. Types of data requested to inform December 2025 Sep 29 COVID-19 vaccine antigen composition deliberations. 2025. Available from: https:\/\/www.who.int\/news\/item\/29-09-2025-types-of-data-requested-to-inform-december-2025-covid-19-vaccine-antigen-composition-deliberations."},{"key":"1176_CR78","unstructured":"World Health Organization. Standing recommendations for COVID-19 issued by the Director-General of the World health Organization (WHO) in accordance with the International health regulatons. 2005. (IHR). 2023 Aug 9. Available from :https:\/\/cdn.who.int\/media\/docs\/default-source\/documents\/ihr\/covid-19_standing-recommendations_9-august-2023.pdf."},{"key":"1176_CR79","unstructured":"World Health Organization. Implementation of the international health regulations (2005). Extension of the standing recommendations for COVID-10. A\/78\/INF.7; 14 May 2025. Available from: https:\/\/apps.who.int\/gb\/ebwha\/pdf_files\/WHA78\/A78_INF7-en.pdf."},{"key":"1176_CR80","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1017\/9781108757683.012","volume-title":"The shifting landscape of global trade governance","author":"O Serrano","year":"2019","unstructured":"Serrano O, Burri M. TRIPS implementation in developing countries: likely scenarios to 2025. In: Elsig M, Hahn M, Spilker G, editors. The shifting landscape of global trade governance. World Trade Forum. Cambridge University Press; 2019. p. 275\u201394."},{"key":"1176_CR81","unstructured":"Kembabazi A. COVID-19 diagnostics and therapeutics: supply, demand, and TRIPS Agreement flexibilities, before the United States International Trade Commission Investigation No. 332-596. Initiative for Social and Economic Rights. 2023 Mar 29;3."},{"key":"1176_CR82","unstructured":"Baker BK, For U.S. International Trade Commission Investigation No. COVID-19 diagnostics and therapeutics: supply, demand, and TRIPS Agreement flexibilities. 332-596. 2023 Mar 15. p. 1."},{"key":"1176_CR83","unstructured":"Reuters S. Africa not planning to buy Pfizer\u2019s covid pill for public sector. Reuters. 2022 Apr 29. Available from: https:\/\/finance.yahoo.com\/news\/africa-not-planning-buy-pfizers-073311851.html?guccounter=1."},{"key":"1176_CR84","unstructured":"Rahman FA, et al. Mapping access Gaps in COVID-19: results from 14 countries and territories. Matahari global solutions. 2022 Aug. Available from: https:\/\/app.box.com\/s\/ewdjytgt0tk0fdgmqnlm4l30hmdyevxw.p.11."},{"key":"1176_CR85","unstructured":"Medicines patent pool. MedsPaL [Internet]. Available from: https:\/\/www.medspal.org\/?disease_area%5B%5D=COVID-19%26disease_area%5B%5D=COVID-19+(drug+candidate)%26page=1."},{"key":"1176_CR86","doi-asserted-by":"crossref","unstructured":"Gotham D, et al. Public investments in the development of GeneXpert molecular diagnostic technology. PLoS ONE. 2021;16(8). Available from: https:\/\/journals.plos.org\/plosone\/article?id=10.1371\/journal.pone.0256883.","DOI":"10.1371\/journal.pone.0256883"},{"key":"1176_CR87","unstructured":"World Health Organization. Six in seven COVID-19 infections go undetected in Africa. 2021 Oct 14. Available from: https:\/\/www.afro.who.int\/news\/six-seven-covid-19-infections-go-undetected-africa."},{"key":"1176_CR88","unstructured":"Nations, United. COVID-19 testing in LDCs - status report of 31.Dec 2022. 2022 Dec. Available from: https:\/\/www.un.org\/development\/desa\/dpad\/wp-content\/uploads\/sites\/45\/LDC-testing-31-Dec-22.pdf."},{"key":"1176_CR89","unstructured":"Us Food and drug administration. Know your treatment options for COVID-19. 2023 Jun 28. Available from: https:\/\/www.fda.gov\/consumers\/consumer-updates\/know-your-treatment-options-covid-19."},{"key":"1176_CR90","unstructured":"Biotechnology innovation Organization. BIO COVID-19 Therapeutic development tracker. Available from: https:\/\/public.tableau.com\/app\/profile\/chad.wessel\/viz\/BIOCovid-19TherapeuticDevelopmentTrackerPublic_16395826570090\/BIOCOVID-19TherapeuticDevelopmentTracker (The tracker was last updated on 22 June 2023."},{"key":"1176_CR91","doi-asserted-by":"crossref","unstructured":"Kumar M, Bharti N. Why patent waiver for covid-19 vaccines and pharmaceuticals? J World Intellect Prop. 2023;205.","DOI":"10.1111\/jwip.12269"},{"key":"1176_CR92","unstructured":"Food and drug administration. Know your treatment options for COVID-19. 2021 Mar 11. Available from: https:\/\/www.fda.gov\/consumers\/consumer-updates\/know-your-treatment-options-covid-19."},{"key":"1176_CR93","unstructured":"National Foreign Trade Council. Investigation No. 332\u2013596 - covid 19 diagnostics and therapeutics: supply, demand, and TRIPS Agreement flexibilities. Statement of The National Foreign Trade Council. p. 5."},{"key":"1176_CR94","unstructured":"World Trade Organization. Agreement On Trade-Related Aspects Of Intellectual Property Rights (TRIPS Agreem)."},{"key":"1176_CR95","unstructured":"Third World Network. re: post hearing Brief by Third World Network -. Investigation No. 332-596. 2023 Apr 12. p. 8."},{"key":"1176_CR96","unstructured":"World Health Organization. Standing recommendations for COVID-19 issued by the Director-General of the World health Organization (WHO) in accordance with the International health regulations. 2005 (IHR). 2023 Aug 9. Available from:https:\/\/cdn.who.int\/media\/docs\/default-source\/documents\/ihr\/covid-19_standing-recommendations_9-august-2023.pdf?sfvrsn=805ad4e4_8%26download=true."},{"key":"1176_CR97","unstructured":"Karlis N. Who leader says COVID-19 is \u2018still a pandemic\u2019. Salon. 2024 Jan 4. Available from: https:\/\/www.salon.com\/2024\/01\/04\/leader-says-19-is-still-a-pandemic\/."},{"key":"1176_CR98","doi-asserted-by":"publisher","unstructured":"Sampat BN. A survey of empirical evidence on patents. NBER working paper 2583. 2018. Available from: https:\/\/doi.org\/10.3386\/w25383.","DOI":"10.3386\/w25383"},{"key":"1176_CR99","unstructured":"World Trade Organization. Declaration on the TRIPS Agreement and public health. WTO Doc WT\/MIN(01)\/DEC\/2. 2001 Nov 14. para. 4."},{"key":"1176_CR100","unstructured":"Panel Report, Australia - Certain Measures Concerning Trademarks, Geographical Indications and Other Plain Packaging Requirements Applicable to Tobacco Products, WTO Docs WT\/DS435\/R, WT\/DS441\/R, WT\/DS458\/R, WT\/DS467\/R. 2018 June 28;7.240."},{"key":"1176_CR101","unstructured":"Panel report, Canada - patent protection for pharmaceutical products. WTO Doc WT\/DS114\/R. 2000, March, 17;7.20."},{"issue":"6","key":"1176_CR102","doi-asserted-by":"publisher","first-page":"679","DOI":"10.2139\/ssrn.2500784","volume":"45","author":"M Lamping","year":"2014","unstructured":"Lamping M, et al. Declaration on patent protection: regulatory Sovereignty under TRIPS. IIC -. Int Rev Intellect Prop Compet Law. 2014;45(6):679\u201398. Available from: https:\/\/doi.org\/10.2139\/ssrn.2500784.","journal-title":"Int Rev Intellect Prop Compet Law"},{"key":"1176_CR103","unstructured":"Correa CM, Correa JI. Manufacturing for export: a TRIPS-Consistent Pro-Competitive exception. Research paper No.155. Geneva: South Centre; 2022. Available from: https:\/\/www.southcentre.int\/wp-content\/uploads\/2022\/05\/RP155_Manufacturing-for-Export-A-TRIPS-Consistent-Pro-Competitive-Exception_EN.pdf."},{"key":"1176_CR104","unstructured":"South Centre. COVID-19 pandemic: access to Prevention and treatment is a matter of national and International security. Open letter from Carlos Correa, Executive Director of the South Centre to who, WIPO and WTO Directors-General. 2020 Apr 4. Available from: https:\/\/www.southcentre.int\/wp-content\/uploads\/2020\/04\/COVID-19-Open-Letter-REV.pdf."},{"key":"1176_CR105","first-page":"7","volume":"22","author":"MZ Abbas","year":"2021","unstructured":"Abbas MZ. The COVID-19 pandemic and Trade-related security exceptions: an analysis of the flexibility under International law. ANZSIL Perspect. 2021;22:7\u201311. Available from: https:\/\/infojustice.org\/archives\/43177.","journal-title":"ANZSIL Perspect"},{"key":"1176_CR106","unstructured":"World Trade Organization. WTO document WT\/DS512\/R. 2019 Apr 5. Available from: https:\/\/docs.wto.org\/dol2fe\/Pages\/SS\/directdoc.aspx?filename=q:\/WT\/DS\/512R.pdf%26Open=True."}],"container-title":["Globalization and Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12992-025-01176-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12992-025-01176-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12992-025-01176-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T11:18:54Z","timestamp":1768994334000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12992-025-01176-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":107,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1176"],"URL":"https:\/\/doi.org\/10.1186\/s12992-025-01176-7","relation":{},"ISSN":["1744-8603"],"issn-type":[{"value":"1744-8603","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"assertion":[{"value":"30 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Decleartion"}},{"value":"Not applicable. Ethical approval was not required for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9"}}